Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Gilead Sciences Inc (GILD)

Gilead Sciences Inc (GILD)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 160,184,192
  • Shares Outstanding, K 1,240,680
  • Annual Sales, $ 28,754 M
  • Annual Income, $ 480,000 K
  • EBIT $ 10,490 M
  • EBITDA $ 13,257 M
  • 60-Month Beta 0.33
  • Price/Sales 5.60
  • Price/Cash Flow 18.07
  • Price/Book 7.18

Options Overview Details

View History
  • Implied Volatility 30.69% (-0.40%)
  • Historical Volatility 28.04%
  • IV Percentile 61%
  • IV Rank 32.44%
  • IV High 49.97% on 04/08/25
  • IV Low 21.43% on 02/12/25
  • Expected Move (DTE 1) 0.86 (0.65%)
  • Put/Call Vol Ratio 0.19
  • Today's Volume 15,024
  • Volume Avg (30-Day) 8,502
  • Put/Call OI Ratio 0.60
  • Today's Open Interest 132,928
  • Open Int (30-Day) 162,144
  • Expected Range 131.13 to 132.85

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 30 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate 1.86
  • Number of Estimates 8
  • High Estimate 1.98
  • Low Estimate 1.72
  • Prior Year 1.90
  • Growth Rate Est. (year over year) -2.11%

Price Performance

See More
Period Period Low Period High Performance
1-Month
116.88 +12.57%
on 01/05/26
133.10 -1.15%
on 01/22/26
+7.41 (+5.97%)
since 12/22/25
3-Month
114.02 +15.39%
on 10/31/25
133.10 -1.15%
on 01/22/26
+10.11 (+8.32%)
since 10/22/25
52-Week
92.21 +42.69%
on 01/23/25
133.10 -1.15%
on 01/22/26
+38.53 (+41.41%)
since 01/22/25

Most Recent Stories

More News
New England Journal of Medicine Publishes Phase 3 ASCENT-04/KEYNOTE-D19 Results Supporting Trodelvy® Plus Keytruda® as a Potential New Standard of Care in First-line PD-L1+ Metastatic Triple-negative Breast Cancer

– Combination Reduced the Risk of Death or Disease Progression by 35% Versus Standard of Care in Frontline PD-L1+ Metastatic TNBC Setting –

GILD : 131.07 (+1.52%)
Gilead Sciences Earnings Preview: What to Expect

Gilead Sciences is expected to release its fiscal fourth-quarter earnings soon, and analysts project a decline in EPS.

XLV : 158.34 (+0.05%)
$SPX : 6,913.78 (+0.56%)
GILD : 131.07 (+1.52%)
Gilead Sciences (GILD): Buy, Sell, or Hold Post Q3 Earnings?

Gilead Sciences (GILD): Buy, Sell, or Hold Post Q3 Earnings?

GILD : 131.07 (+1.52%)
Stocks Finish Higher on Strength in Chip Makers and Energy Producers

The S&P 500 Index ($SPX ) (SPY ) on Monday closed up +0.64%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed up +1.23%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up +0.77%. March E-mini S&P...

MSTR : 162.78 (-0.63%)
MPC : 174.46 (-1.70%)
HL : 31.45 (+8.90%)
CDE : 25.83 (+12.75%)
ADI : 307.53 (+0.84%)
GLXY : 30.73 (-5.30%)
JNJ : 219.26 (+0.57%)
SLB : 49.26 (+1.53%)
QXO : 24.07 (+2.56%)
AMGN : 348.16 (+1.33%)
COIN : 224.87 (-0.91%)
PNR : 108.47 (+1.23%)
3 Cash-Flow Machines Investors May Want Heading Into 2026

A company's cash flow can reveal its day-to-day success and sustainability, and these three firms are all thriving when it comes to cash generation.

QCOM : 157.73 (+0.87%)
XOM : 133.88 (+0.20%)
GILD : 131.07 (+1.52%)
Stock Index Futures Slip in Weak End to a Banner Year

March S&P 500 E-Mini futures (ESH26) are down -0.20%, and March Nasdaq 100 E-Mini futures (NQH26) are down -0.32% this morning, pointing to a weak start on Wall Street in the final trading session of 2025....

KLAC : 1,508.88 (-0.73%)
AMAT : 318.93 (-1.94%)
GOOGL : 330.48 (+0.64%)
META : 646.13 (+5.41%)
C : 115.37 (+1.33%)
MOH : 198.33 (+1.92%)
VRTX : 465.22 (+0.88%)
NKE : 65.56 (+0.23%)
SEPL.LN : 331.500 (-0.30%)
ESH26 : 6,946.50 (+0.53%)
ANGH : 2.90 (+3.71%)
NQH26 : 25,637.25 (+0.65%)
Stocks Fall Slightly in Thin Holiday Trade

The S&P 500 Index ($SPX ) (SPY ) on Tuesday closed down -0.14%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed down -0.20%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed down -0.25%. March E-mini...

C : 115.37 (+1.33%)
RARE : 23.42 (+2.95%)
HL : 31.45 (+8.90%)
SLB : 49.26 (+1.53%)
$IUXX : 25,499.39 (+0.68%)
ZNH26 : 111-190 (-0.06%)
OXY : 43.15 (-0.83%)
ESH26 : 6,946.50 (+0.53%)
FANG : 151.49 (-0.99%)
JBL : 245.32 (-3.09%)
$DOWI : 49,433.04 (+0.73%)
SPY : 689.15 (+0.55%)
Stocks Slip as Bond Yields Rise

The S&P 500 Index ($SPX ) (SPY ) today is down -0.12%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -0.25%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -0.11%. March E-mini S&P futures...

C : 115.37 (+1.33%)
RARE : 23.42 (+2.95%)
SLB : 49.26 (+1.53%)
$IUXX : 25,499.39 (+0.68%)
ZNH26 : 111-190 (-0.06%)
OXY : 43.15 (-0.83%)
ESH26 : 6,946.50 (+0.53%)
FANG : 151.49 (-0.99%)
$DOWI : 49,433.04 (+0.73%)
SPY : 689.15 (+0.55%)
DIA : 494.26 (+0.70%)
INSM : 159.49 (+2.03%)
Gilead Sciences to Present at Upcoming Investor Conference

Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conference: J.P. Morgan Healthcare Conference on Monday, January...

GILD : 131.07 (+1.52%)
Gilead Sciences Exercises Option to License Assembly Biosciences’ Helicase-Primase Inhibitor Programs for Recurrent Genital Herpes

– Weekly Oral Helicase-Primase Inhibitor Programs' Early Data Potentially Supportive of First New Treatment for Recurrent Genital Herpes in 25 Years –

ASMB : 27.54 (+4.52%)
GILD : 131.07 (+1.52%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy and ranks in the Top 1% of all short term signal directions.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Gilead Sciences is a pioneer in developing drugs for the treatment of human immunodeficiency virus, liver diseases, hematology/oncology diseases and inflammation/respiratory diseases. The company has a strong HIV franchise with key HIV/AIDS therapies like tenofovir alafenamide based products - Genvoya,...

See More

Key Turning Points

3rd Resistance Point 138.15
2nd Resistance Point 133.77
1st Resistance Point 131.44
Last Price 131.07
1st Support Level 124.73
2nd Support Level 120.35
3rd Support Level 118.02

See More

52-Week High 133.10
Last Price 131.07
Fibonacci 61.8% 117.48
Fibonacci 50% 112.65
Fibonacci 38.2% 107.83
52-Week Low 92.21

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar